Developing small-molecule drugs for triplet-repeat-expansion diseases.
| Date | Round | Amount |
|---|---|---|
| Oct 2024 | Series A LoQus23 Therapeutics, a Cambridge biotech targeting triplet-repeat diseases, raised a GBP35M Series A led by Forbion. | $45M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.